Cyberonics to start VNS (vagus nerve stimulation) migraine trial in the US:
This article was originally published in Clinica
The US FDA has given Cyberonics the go-ahead to begin a pilot study to assess its implantable vagus nerve stimulation (VNS) device as a treatment for chronic migraine headache. The firm's NeuroCybernetic Prosthesis will be tested in 30 patients at four medical centres. It will be used to provide left cervical (neck area) VNS therapy in a similar fashion to the way it is used in patients with epilepsy, depression and Alzheimer's disease, says the Houston, Texas company. The US National Headache Foundation says that there are 28 million migraine sufferers in the US.